Rezolute, Inc. (NASDAQ:RZLT) CEO Nevan C. Elam Buys 12,302 Shares

Rezolute, Inc. (NASDAQ:RZLT) CEO Nevan C. Elam purchased 12,302 shares of the firm’s stock in a transaction dated Thursday, March 27th. The stock was acquired at an average cost of $2.85 per share, with a total value of $35,060.70. Following the completion of the acquisition, the chief executive officer now directly owns 224,119 shares in the company, valued at approximately $638,739.15. This trade represents a 5.81 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Rezolute Price Performance

Shares of Rezolute stock opened at $2.90 on Tuesday. Rezolute, Inc. has a 1-year low of $2.22 and a 1-year high of $6.19. The business’s fifty day moving average price is $4.22 and its two-hundred day moving average price is $4.73. The company has a market capitalization of $175.55 million, a P/E ratio of -2.38 and a beta of 0.95.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. On average, research analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Institutional Trading of Rezolute

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. bought a new position in shares of Rezolute in the third quarter valued at approximately $42,000. Alpine Global Management LLC acquired a new stake in Rezolute in the fourth quarter worth approximately $54,000. MML Investors Services LLC acquired a new stake in Rezolute in the third quarter worth approximately $57,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Rezolute in the 3rd quarter worth $65,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock valued at $112,000 after buying an additional 9,000 shares during the period. 82.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RZLT. Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Rezolute in a research report on Thursday, February 13th. Guggenheim reaffirmed a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. Finally, JMP Securities boosted their price target on shares of Rezolute from $8.00 to $9.00 and gave the company a “market outperform” rating in a report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Rezolute presently has an average rating of “Buy” and an average price target of $24.38.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.